Characteristics of recipients of unrelated-donor transplants
| Disease . | No. of patients . | Median (range) age, y . | No. (%) female . |
|---|---|---|---|
| CMLCP | 1223 | 37 (2-59) | 527 (43) |
| CML2CP | 147 | 34 (4-55) | 59 (40) |
| CMLAP | 295 | 38 (4-62) | 113 (38) |
| CMLBP | 78 | 37 (5-57) | 23 (29) |
| ALL1 | 228 | 16 (0-53) | 100 (44) |
| ALL2 | 385 | 13 (0-54) | 171 (44) |
| ALL3+ | 139 | 12 (1-40) | 51 (37) |
| ALL/RLPS | 262 | 23 (0-54) | 89 (34) |
| AML1 | 231 | 27 (0-65) | 102 (44) |
| AML2 | 280 | 26 (1-58) | 126 (45) |
| AML3+/RLPS | 599 | 34 (0-62) | 262 (44) |
| MDS | 476 | 37 (0-63) | 211 (44) |
| Other leukemia | 132 | 26 (0-66) | 53 (40) |
| Other malignant disease | 237 | 37 (2-58) | 81 (34) |
| SAA | 198 | 16 (0-52) | 77 (39) |
| Other nonmalignant disease | 336 | 3 (0-48) | 126 (38) |
| Total | 5246 | 29 (0-66) | 2171 (41) |
| Disease . | No. of patients . | Median (range) age, y . | No. (%) female . |
|---|---|---|---|
| CMLCP | 1223 | 37 (2-59) | 527 (43) |
| CML2CP | 147 | 34 (4-55) | 59 (40) |
| CMLAP | 295 | 38 (4-62) | 113 (38) |
| CMLBP | 78 | 37 (5-57) | 23 (29) |
| ALL1 | 228 | 16 (0-53) | 100 (44) |
| ALL2 | 385 | 13 (0-54) | 171 (44) |
| ALL3+ | 139 | 12 (1-40) | 51 (37) |
| ALL/RLPS | 262 | 23 (0-54) | 89 (34) |
| AML1 | 231 | 27 (0-65) | 102 (44) |
| AML2 | 280 | 26 (1-58) | 126 (45) |
| AML3+/RLPS | 599 | 34 (0-62) | 262 (44) |
| MDS | 476 | 37 (0-63) | 211 (44) |
| Other leukemia | 132 | 26 (0-66) | 53 (40) |
| Other malignant disease | 237 | 37 (2-58) | 81 (34) |
| SAA | 198 | 16 (0-52) | 77 (39) |
| Other nonmalignant disease | 336 | 3 (0-48) | 126 (38) |
| Total | 5246 | 29 (0-66) | 2171 (41) |
CMLCP indicates chronic myelogenous leukemia in first chronic phase; CML2CP, CML in 2nd chronic phase; CMLAP, CML in accelerated phase; CMLBP, CML in blast phase; ALL1, acute lymphoblastic leukemia in first complete remission (CR); ALL2, ALL in 2nd CR; ALL3+, ALL in 3rd or higher CR; RLPS, relapse; AML1, acute myelogenous leukemia in first CR; AML2, AML in 2nd CR; AML3+, AML in 3rd or higher CR; MDS, myelodysplastic syndrome; and SAA, severe aplastic anemia.